Enzyme News and Research

RSS

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

DuPont completes Danisco tender offer for DKK 700 per share

DuPont, through its wholly owned subsidiary DuPont Denmark Holding ApS, announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Danisco for DKK 700 cash per share.

16 May 2011

Study reveals crucial role of histone deacetylases in type 2 diabetes

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

16 May 2011

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery.

16 May 2011

Researchers uncover unexpected role of estrogen receptors in brain inflammation

Researchers have uncovered an unexpected role for estrogen receptors in the brain in keeping inflammation under control. The findings reported in the May 13 issue of the Cell Press journal Cell may have important implications for the treatment of multiple sclerosis (MS) and many other neurodegenerative diseases.

13 May 2011

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

New research shows that elevated levels of cardiac troponin T (cTnT) or I (cTnI) in patients who had angioplasty indicate a higher risk of all-cause mortality and long-term adverse events such as heart attack.

13 May 2011

UCSD scientists discover steroid hormone that inhibits brain inflammation

Researchers at the University of California, San Diego School of Medicine have discovered a steroid hormone that inhibits inflammation in the brain. The findings, to be published in the May 13 issue of the journal Cell, have implications for understanding the exaggerated inflammatory responses that are characteristic features of numerous neurodegenerative diseases.

13 May 2011

Scientists discover enzyme that controls K-Ras gene responsible for lung cancer growth

Cancer Research UK scientists have discovered that an enzyme called C-Raf controls a hugely important gene responsible for the development of lung cancer, according to research published in Cancer Discovery.

13 May 2011

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report from CG400549's Phase I Multiple Ascending Dose Study has just been received.

12 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

Belgian physicians report they have cured a young patient with extensively drug-resistant tuberculosis (XDR-TB) using a novel two-drug combination developed by researchers at Albert Einstein College of Medicine of Yeshiva University. The report, published in the Pediatric Infectious Disease Journal, marks the first known clinical use of this treatment for XDR-TB, the most deadly form of the disease.

11 May 2011

FDA clears Meridian's new C. difficile immunoassay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier C. difficile GDH.

11 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

Researchers analyze gene expression profiles to understand molecular mechanisms behind various diseases

Over the past decades, researchers seeking to understand molecular mechanisms underlying various diseases, notably cancer, have taken advantage of DNA microarrays to interrogate tissues specimen of patients for the expression status of thousands of genes at once.

9 May 2011

Cancer researchers help unlock cellular-level function of telomerase enzyme

Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth.

7 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

PhotoMedex introduces DNA Damage Control sunscreens

PhotoMedex, Inc. a leading supplier of advanced, clinical skincare and medical laser products, today introduced DNA Damage Control, the breakthrough treatment sunscreens that feature advanced photoprotection with DNA repair technology.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

Physical exercise generates nitric oxide intermediates critical for cardioprotection

Exercise both reduces the risk of a heart attack and protects the heart from injury if a heart attack does occur. For years, doctors have been trying to dissect how this second benefit of exercise works, with the aim of finding ways to protect the heart after a heart attack.

5 May 2011

Enzyme News and Research

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

DuPont completes Danisco tender offer for DKK 700 per share

Study reveals crucial role of histone deacetylases in type 2 diabetes

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Researchers uncover unexpected role of estrogen receptors in brain inflammation

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

UCSD scientists discover steroid hormone that inhibits brain inflammation

Scientists discover enzyme that controls K-Ras gene responsible for lung cancer growth

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

FDA clears Meridian's new C. difficile immunoassay

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

Researchers analyze gene expression profiles to understand molecular mechanisms behind various diseases

Cancer researchers help unlock cellular-level function of telomerase enzyme

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

PhotoMedex introduces DNA Damage Control sunscreens

Clinical study: Celecoxib drug may treat breast cancer

Physical exercise generates nitric oxide intermediates critical for cardioprotection

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo